ABSTRACT
A thorough understanding of the molecular genes of head and neck cancers (HNCs) now permits us to develop certain novel therapies which can target components specific to the molecular genetic apparatus that support development of tumor, growth, and spread. EGFR is one such specific intriguing target. It is a transmembrane tyrosine kinase receptor which functions as a central transducer of multiple signaling pathways that are involved in tumor cell growth, angiogenesis, and invasion.
